CA 15-3 has been most widely used as a serum tumor marker in follow-up and detection of breast cancer recurrence. In this study we have specifically focused upon the prognostic implications and utility of preoperative CA 15-3 levels. We have identified on our database 414 patients with breast cancer in whom serial levels of the serum tumor marker CA 15-3 had been determined at diagnosis and follow-up. We have analyzed the follow-up and clinical outcomes in these patients and from this data we have assessed the potential of CA 15-3 as a predictor of five-year overall and diseasefree survival. Our results show that an initially elevated CA 15-3 level is associated with a very poor prognosis in both early and late stage disease. Elevated pre-biopsy CA 15-3 levels are associated with 14% five-year disease-free survival rates and 17% overall survival rates at five years. In contrast, normal CA 15-3 levels are associated with 47% five-year disease-free survival rates and 54% overall survival rates at five years (p<0.01). Comparison of five-year survival rates between patients with elevated and normal CA 15-3 levels in early breast cancer (stage I and II) also showed significant differences, with survival being 41% and 75%, respectively (p<0.01). (Int J Biol Markers, 2000; 15: 340-2) 
INTRODUCTION
An essential prerequisite for the planning of effective adjuvant therapeutic strategies in breast cancer is the identification at an early stage of patients at high risk of recurrence. Serum tumor markers have been amongst the many prognostic variables that have been studied in attempts to refine the decision-making process.
CA 15-3 is a circulating serum carcinoma-associated antigen which is defined by monoclonal antibodies raised against breast carcinoma tissue and milk fat globule membrane. CA 15-3 has become the most widely accepted serum tumor marker in breast cancer. At this hospital we have a prospectively collected computer database of all epidemiological, clinical, histological, biochemical, radiological and follow-up information of all patients diagnosed with breast cancer. As part of this database CA 15-3 levels at the time of diagnosis and during follow-up have been recorded for over 10 years.
We have previously shown that CA 15-3 levels correlate with tumor size, nodal status and stage in primary breast cancer (1) . In addition, we have shown that rising CA 15-3 levels correlate with disease progression and occur before radiological evidence of this process (2, 3) . Others have shown similar results in defining a role for CA 15-3 in the diagnosis, staging and detection of recurrence in breast cancer (4) (5) (6) .
In this study we have specifically looked at the prognostic value of CA 15-3 levels at the time of initial diagnosis of breast cancer. We looked at the prognostic implications, in terms of five-year overall and disease-free survival, of serum CA 15-3 levels prior to definitive surgery in breast cancer patients. From our database we identified women with breast cancer who had a preoperative CA 15-3 level and on whom we had complete follow-up available. This follow-up information was correlated with CA 15-3 levels at time of diagnosis.
MATERIALS AND METHODS
The National Breast Cancer Research Institute database is a prospectively collected record of all epidemiological, clinical, histological, biochemical, radiological and follow-up information of all patients diagnosed with breast cancer at this hospital. We identified on this data-
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National Breast Cancer Research Institute, University College Hospital Galway, Galway -Ireland base 414 patients with breast cancer in whom serial levels of the serum tumor marker CA 15-3 had been determined during diagnosis and follow-up. The normal cutoff level for CA 15-3 was taken as 30 U/mL. CA 15-3 levels were quantified using a commercially available immunoradiometric assay kit (CA 15-3 solid phase ELISA system, CIS Biointernational, ORIS Group, Gif-sur-Yvette, France). Staging of disease was performed according to the UICC (1987) criteria.
The CA 15-3 serum sample was in all cases taken prior to definitive surgery (segmentectomy or mastectomy). If an open biopsy was performed prior to definitive surgery, only patients with CA 15-3 levels taken before this intervention were included in the study.
The patient cohort thus identified was analyzed with follow-up and clinical outcomes related to initial CA 15-3 levels. The indices of five-year overall and disease-free survival were used to assess the utility of preoperative serum CA 15-3 levels in predicting prognosis. Recurrence was defined as histologically or radiologically proven metastases and included locoregional recurrence. The perioperative workup included chest x-ray, liver function tests and isotope bone scan. Each patient was seen at three-monthly intervals for the first year, at sixmonthly intervals for the next two years, and yearly thereafter. At each visit a clinical examination was performed, serum CA 15-3 levels were determined and other investigations were performed as clinically indicated.
RESULTS
A total of 414 women were identified who had a preoperative CA 15-3 level and complete follow-up available. The UICC staging was as follows: 99 stage I, 227 stage II, 43 stage III and 45 stage IV.
We first looked at the implications of an initially elevated CA 15-3 level for disease-free survival and overall survival. In patients with an initially elevated CA 15-3 level (>30 UI/mL) the five-year disease-free survival was 14%, compared with 47% for those with a normal CA 15-3 level (p<0.01). The five-year overall survival was 17% for those with elevated CA 15-3 compared with 54% for those with a normal CA 15-3 level (p<0.01). We looked at the same parameters in patients with stage I and II breast cancer and found five-year disease-free survival and overall survival in those with an initially elevated CA 15-3 level to be 26% and 41%, respectively. In stage I and II patients with initially normal CA 15-3 levels five-year disease-free survival and overall survival were 50% and 75%, respectively (p<0.05) ( Table I) .
The sensitivity, specificity, positive and negative predictive values for five-year disease-free survival are shown in Table II . The sensitivity, specificity, positive and negative predictive values for five-year overall survival are shown in Table III .
DISCUSSION
CA 15-3 has become established as a tumor marker with clinical utility in the follow-up of patients with breast cancer. It can detect recurrence providing a lead time ahead of other diagnostic modalities (2, 4, 5) . It has been suggested that CA 15-3 levels may be taken into account when deciding upon treatment strategy and interventions as well as monitoring response to therapy (7, 8) . It also has a role in determining the significance of equivocal lesions on bone scan where a normal CA 15-3 level has a negative predictive value of 97% (6) . In this study we have assessed specifically the prognostic utility of CA 15-3 level estimation prior to definitive surgery.
The results show that an elevated CA 15-3 level prior to initial surgery is an ominous prognostic feature associated with 14% five-year disease-free survival and 17% overall survival. This compares with 47% disease-free survival and 54% overall survival in those with a normal CA 15-3 level prior to initial surgery. When patients with stage I and II disease are assessed there is also a negative impact upon prognosis associated with an increased CA 15-3 level. In these patients an elevated CA 15-3 level prior to initial surgery is associated with 26% five-year disease-free survival and 41% overall survival. This compares with 50% disease-free survival and 75% overall survival in those with a normal CA 15-3 level prior to initial surgery. In summary, our results show that an initially elevated CA 15-3 level is a marker of enhanced risk of recurrence and mortality. This effect is seen in both early and late stage breast cancer. CA 15-3 and in particular an elevated level at the time of diagnosis may be an additional prognostic indicator at the time of diagnosis of breast cancer.
